Inhibitors of antigen presentation by MHC class II molecules...

Details Inhibitors of antigen presentation by MHC class II molecules... Inhibitors of antigen presentation by MHC class II molecules...

2004-02-13

2008-10-21

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C053S329000, C053S330000

Reexamination Certificate

active

07439231

ABSTRACT:
The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

REFERENCES:
patent: 4224316 (1980-09-01), Momany
patent: 4839344 (1989-06-01), Bowers et al.
patent: 5624902 (1997-04-01), Blondelle et al.
patent: 5817629 (1998-10-01), Warren et al.
patent: 5858980 (1999-01-01), Weiner et al.
patent: 5874531 (1999-02-01), Strominger et al.
patent: 6207644 (2001-03-01), Luke et al.
patent: 6355617 (2002-03-01), Luke et al.
patent: 2002/0133027 (2002-09-01), Smith, III et al.
patent: WO 94/20127 (1994-09-01), None
patent: WO 96/12731 (1996-05-01), None
patent: WO98/12212 (1998-03-01), None
patent: WO 03/082197 (2003-10-01), None
Yoo, Sung-eun. ‘Angiotensin II Receptor Antagonists for New Antihypertensives’ Korean J. of Med. Chem. vol. 6, No. 2, pp. 325-328. 1996.
Fiorenza et al., “Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules,” Nature Biotechnology 17:562-567 (1999).
Lehmann et al., “Selective peptidomimetic blockers of autoantigen presentation: a novel therapeutic approach to autoimmune disease,” Trends in Pharmacological Sciences (Elsevier, Haywarth, GB) 21(3):79-80.
Adorini, et al., (1988), “In Vivo Competition Between Self Peptides and Foreign Antigens in T-cell Activation”,Nature, 334, 623-625.
Bolin, et al., (2000), “Peptide and Peptide Mimetic Inhibitors of Antigen Presentation by HLA-DR Class II MHC Molecules, Design, Structure-Activity Relationships, and X-ray Crystal Structures”,J. Med. Chem., 43, 2135-2148.
Falcioni, et al., (1999), “Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules”,Nature Biotechnology, 17, 562-567.
Giordano, M. et al. (2002), “Genetics of Multiple Sclerosis—Linkage and Association Studies”,Am. J. Pharmacogenomics 2:37-58.
Hammer, J. et al. (1993), “Promiscuous and Allele-Specific Anchors in HLA-DR-Binding Peptides”,Cell 74:197-203.
Ishioka, et al., (1994), “Failure to Demonstrate Long-Lived MHC Saturation Both In Vitro and In Vivo”,J. Immunol. 152, 4310-4319.
Lamont, et al. (1990), “The Use of Peptide Analogs with Improved Stability and MHC Binding Capacity to Inhibit Antigen Presentation In Vitro and In Vivo”,J. Immunol. 144, 2493-2498.
Smith et al. (1998), “Crystal Structure of HLA-DR2 (DRA*0101,DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein”,J. Exp. Med. 188:1511-1520.
Stern et al. (1994), “Crystal Structure of the Human Class II MHC Protein HLA-DR1 Complexed with an Influenza Virus Peptide”,Nature 368:215-221.
Wucherpfennig et al. (1994), “Structural Requirements for Binding of an Immunodominant Myelin Basic Protein Peptide to DR2 Isotypes and for Its Recognition by Human T Cell Clones”,J. Exp. Med. 179:279-290.
Yusuf-Makagiansar et. al. (2002), “Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases”,Med. Res. Rev. 22(2):146-167.

Affiliated with

Also associated with

Rating

Inhibitors of antigen presentation by MHC class II molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of antigen presentation by MHC class II molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of antigen presentation by MHC class II molecules... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4004185